Mitochondrial Functions and Oxidative Stress in ALS Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-02-28

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients) and is an independent prognostic factor. One of the implicated factors is the increase of resting energy expenditure (REE) which can be found in about 50 % of ALS patients. The origin of this hypermetabolism is currently unknown but could be located in the mitochondria. In fact, some studies have found mitochondrial abnormalities and the existence of an oxidative stress. Thus, the aim of this study is to characterize the mitochondrial abnormalities and the oxidant/antioxidant status of ALS patients and to determine their relationship with the metabolic status, hypermetabolism or normometabolism. Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy volunteers paired for age and sex.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients

NCT02152449

Amyotrophic Lateral Sclerosis (ALS)

COMPLETED NA

New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.

NCT03984708

Amyotrophic Lateral Sclerosis

COMPLETED NA

Evaluation of Metabolomic Analysis in Early Diagnosis of ALS

NCT01962311

ALS

COMPLETED NA

Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients

NCT02424669

Amyotrophic Lateral Sclerosis (ALS)

UNKNOWN NA

Study of Predictive Factors of Progression of Motor Neurone Disease

NCT02360891

Amyotrophic Lateral Sclerosis Motor Neuron Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients) and is an independent prognostic factor. One of the implicated factors is the increase of resting energy expenditure (REE) which can be found in about 50 % of ALS patients. The origin of this hypermetabolism is currently unknown but could be located in the mitochondria. In fact, some studies have found mitochondrial abnormalities and the existence of an oxidative stress. Thus, the aim of this study is to characterize the mitochondrial abnormalities and the oxidant/antioxidant status of ALS patients and to determine their relationship with the metabolic status, hypermetabolism or normometabolism. Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy volunteers paired for age and sex.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mitochondrial functions and oxidative stress

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female
* age \> 30 years
* definite or probable ALS according to the El Escorial criteria, bulbar or spinal form, ALS diagnosis \< 1 year and treatment by riluzole.

Exclusion Criteria

* family history of ALS,
* oral, enteral or parenteral nutritional supply,
* vitamin or trace element supplementation
* confusing illness (cancer, diabetes, chronic infectious or inflammatory disease,thyroid disorders, recent surgery...),
* current tobacco use,
* alcoholism
* treatment by corticosteroids,
* diuretics,
* anorectics
* NSAIDs
* cytotoxics
* anticoagulants...

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes